Apollomics (APLM) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Apollomics (NASDAQ: APLM):

• 12/28/2025 – Apollomics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/22/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Apollomics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/15/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/22/2025 – Apollomics was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 11/19/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Apollomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.